Phase 3 N=1,455 AZD7442 for Inpatients With COVID-19 (An ACTIV-3/TICO Treatment Trial)
COVID-19
Primary: Number of Participants With Sustained Recovery — 617; 594 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=121 Investigation of the Safety and Pharmacology of Dry Powder Inhalation of Treprostinil
Primary Pulmonary Hypertension
Primary: Incidence of Treatment-Emergent Adverse Events and Serious Adverse Events — 121 Participants
Phase 3 N=467 Changes in NT-proBNP, Safety, and Tolerability in HFpEF Patients With a WHF Event (HFpEF Decompensation) Who Have Been Stabilized and Initiated at the Time of or Within 30 Days Post-decompensation (PARAGLIDE-HF)
Heart Failure With Preserved Ejection Fraction (HFpEF)
Primary: Time-averaged Proportional Change in NT proBNP From Baseline to Weeks 4 and 8 — 0.7200; 0.8425 Geometric Mean Ratio — p=0.0492
Phase 3 N=322 Phase 3 Study of the Safety and Efficacy of OmegaD Softgels in the Treatment of Dry Eye Disease
Dry Eye
Primary: Tear Osmolarity — 13.4; 11.8 mOsm/L
Phase 3 N=421 The Healthy Patterns Sleep Study
Dementia · Alzheimer Disease · Circadian Rhythm Disorders
Primary: Change in the Quality of Life in Alzheimer's Disease (QOL-AD) Scale — 0.56; -0.47 scores on a scale
Phase 3 N=214 Comparing Efficacy and Safety Between Pertuzumab® and Perjeta® in Neoadjuvant Treatment of HER2+ Breast Cancer
HER2-positive Breast Cancer
Primary: Breast Pathological Complete Response (bpCR) — 71; 73 Participants — p=0.54
Phase 3 N=930 Zoliflodacin in Uncomplicated Gonorrhoea
Gonorrhea
Primary: Microbiological Cure Rate for Zoliflodacin Compared to a Combination of a Single Dose of Ceftriaxone and Azithromycin. — 90.9; 96.2 percentage of participants
Phase 3 N=193 RESPONSE: Response to Seladelpar in Subjects With Primary Biliary Cholangitis (PBC) and an Inadequate Control to or an Intolerance to Ursodeoxycholic Acid (UDCA)
Primary Biliary Cholangitis
Primary: Percentage of Participants With Response Criteria for the Composite Endpoint of ALP <1.67 × Upper Limit of Normal (ULN), ≥15% Reduction in ALP, and Total Bilirubin ≤…
Phase 3 N=313 Safety and Immunogenicity of V116 in Adults Living With Human Immunodeficiency Virus (HIV) (V116-007, STRIDE-7)
Pneumococcal Disease
Primary: Percentage of Participants With Solicited Injection-site AEs From Day 1 Through Day 5 Postvaccination in Part A — 3.9; 11.0; 50.3; 82.6 Percentage of Participants
Phase 3 N=322 Tisagenlecleucel in Adult Patients With Aggressive B-cell Non-Hodgkin Lymphoma
Non-Hodgkin Lymphoma
Primary: Event-free Survival (EFS) Per Blinded Independent Review Committee (BIRC) Assessment — 3.0; 3.0 months — p== 0.694
Phase 3 N=76 Azacitidine With or Without Nivolumab or Midostaurin, or Decitabine and Cytarabine Alone in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome
Acute Myeloid Leukemia · Myelodysplastic Syndrome · Myelodysplastic Syndrome/Acute Myeloid Leukemia
Primary: Overall Survival (OS) (Phase II) — 6.2; 5.2; 7.4 months
Phase 3 N=38 A Study of Levetiracetam as Monotherapy or Adjunctive Treatment of Partial Seizures in Pediatric Epileptic Subjects Ranging From 1 Month to Less Than 4 Years of Age
Partial Seizures
Primary: Percent Change in Partial Seizure Frequency Per Week From Baseline to Visit 6 — 24.24 percent change
Phase 3 N=1,030 A Study of Nivolumab or Placebo in Combination With Docetaxel in Men With Advanced Castration-resistant Prostate Cancer
Prostate Cancer
Primary: Radiographic Progressive Free Survival (rPFS) Assessed by Blinded Independent Central Review (BICR) Per Prostate Cancer Working Group 3 (PCWG3) — 9.43; 8.74 months…
Phase 3 N=41 Study of Efficacy and Safety of Secukinumab in Chinese Subjects With Active PsA Compared to Placebo.
Psoriatic Arthritis
Primary: ACR20 Response at Week 16 — 14; 6 Participants
Phase 3 N=70 A Phase II/III Study of Sargramostim
COVID-19
Primary: 2-rank Improvement on a 7-point Ordinal Scale — 9; 8 Number of Days